Skip to main content

Sangamo/Pfizer's Giroctocogene Fitelparvovec Gene Therapy for Hemophilia- Clinical Update

Introduction of Giroctocogene Fitelparvovec Gene Therapy for Hemophilia A

Giroctocogene Fitelparvovec is an investigational gene therapy product for the treatment of Hemophilia A co-developed by Sangamo/Pfizer. Giroctocogene fitelparvovec (SB-525) is a liver-tropic recombinant adeno-associated virus (rAAV6) vector carrying a B-domain–deleted F8 gene that is delivered through a single IV infusion.

Sponsor: Sangamo Therapeutics/ Pfizer
Stage-  Phase 3
Phase 2 - NCT03061201
Phase 3 - NCT04370054 (First Patient Dose) 

Clinical Outcome 
Efficacy: Efficacy was observed with significant reduction of annualized bleeding rate and usage of factor VIII infusion in phase 2 at the vector dose 3e13 vg/kg (viral genome/kg) upto 36 weeks after treatment.

Safety: In phase 2 clinical studies, 4/5 subject at a vector dose of 3e13 vg/kg showed transient elevation of transaminases and required corticosteroid therapy. One treatment related SAE was observed. 

Durability: The gradual decline of the factor VIII activity after peaking at 23-26 weeks was observed in four year follow up of AAV5-FVIII hemophilia treatment developed by Biomarin.  In this phase 2 clinical study, factor VIII peaked at week 9 and the stable expression was observed up to 36 weeks follow up. Longer term study will should provide more information on the durability of the expression. 
...........................................

Sangamo Phase 3 Study (AFFINE) Update

AFFINE is a global Phase 3, open-label, multicenter, single arm study that will evaluate the efficacy and safety of giroctocogene fitelparvovec in patients with moderately severe to severe hemophilia A. 

The primary endpoint is impact on annual bleed rate (ABR) through 12 months following treatment with giroctocogene fitelparvovec, compared to ABR on Factor VIII (FVIII) replacement therapy collected in the Phase 3 lead-in study period. 

Participants will be analyzed throughout the 5-year study period following the single infusion to further assess the durability and efficacy.

On October 7, 2020; the first participant were dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients.
........................................

 Key Finding From Phase 2 (Alta) Study Updated on June 18, 2020

Efficacy from Cohort 4 (3x1013 vg/kg)
  • Steady-state FVIII activity achieved by week 9 post infusion
  • FVIII activity values available up to week 30 and up to week 61
  • Median steady-state (of geometric means since week 9) FVIII activity level 64.2% via central laboratory chromogenic assay
  • No bleeding events 
  • No FVIII infusions beyond initial use of prophylactic factor
Summary of Results from Phase 2 Clinical Study (WHF2020)


.....................................................
Reference
Sangamo Therapeutics
Pfizer
ClinicalTrail.gov
Labels:

Comments

Post a Comment

Popular posts from this blog

Multiple Choice Questions (MCQs) on Diabetes Mellitus: Pathogenesis, Diagnosis and Treatment

                                        MCQs on Diabetes mellitus 1) Diabetes mellitus is a disorder characterized by hyperglycemia.  Which of the following is not the common characteristic features of type 2 diabetes mellitus ? a) Impaired insulin secretion b) Increased Insulin resistance  c) Diabetic ketoacidosis d) Excessive hepatic glucose production 2) Which of the following are the characteristic features of type 1 diabetes mellitus? a) Type 1 diabetes is caused by an absolute deficiency of insulin. b) Type 1 diabetes is associated with the autoimmune destruction of beta cells.  c) Patients with  uncontrolled type 1 diabetes present with diabetic ketoacidosis d) All of the above   3) Which of the following serum measurements are not used for the diagnosis of diabetes mellitus? a) Fasting blood glucose d) Postprandial blood glucose  c) Insulin ...
6 comments
Read More

MCQs on Superficial and Cutaneous Mycoses-Dermatophytes: Medical Mycology

  Multiple Choice Questions on Superficial and Cutaneous Fungal Infections 1. All of the following are examples of common superficial mycoses, EXCEPT ? a) Aspergillosis b) Candidiasis c) Tinea versicolor d) Tinea nigra 2. Which of the following statement regarding Tinea nigra infection is NOT correct? a) Most prevalent in the tropical and subtropical region b) Symptoms include pigmented macules on palm and soles c) Trycophyton spp is the causative fungi d) Common specimen is skin scrapings 3. The fungi Trichosporon commonly causes superficial infection of hair also called white piedra. Which of the following species of Trichosporon causes scalp hair white piedra ? a) T. ovoides b) T. inkin c) T. asahii d) None of the above 4. All of the following are the characteristics of cutaneous mycoses, EXCEPT ? a) The infection of hair, skin, and nails b) The common cause of ringworm in humans only c) Candida spp is associated with the infection d) The keratinize...
3 comments
Read More

MCQs on Human Immunodeficiency Virus (HIV/ AIDS) with answers: Medical Microbiology

Multiple Choice Questions on Human Immunodeficiency Virus (HIV/AIDS) with answers 1) Which virus is associated with acquired immune deficiency syndrome (AIDS) pandemic? A) HIV-2 B) HTLV-1 C) HIV-1 D) HIV-3 2) Which of the following is an important molecule present in the outer membrane of HIV that helps the virus to enter and infect host cells? a) Polysaccharides b) Glycoproteins c) Proteins d) Lipopolysaccharides 3) Select all the incorrect options given below for the common route of transmission of HIV from one person to another? a) Unprotected sexual contact with an infected person b) From infected mother to the fetus c) From the mosquito bite  d) Exposure to contaminated blood and blood products e) Using and sharing the same swimming pool  4) HIV belongs to which of the following genus member of the virus? a) Orthomyxovirus b) Retrovirus c) Parvovirus d) Reovirus 5) All of the following statements regarding HIV infection in human is true, ...
3 comments
Read More